Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) Director Milton C. Ault III bought 59,516 shares of the inventory in a transaction on Wednesday, July twenty third. The shares had been bought at a median value of $2.95, for a complete transaction of $175,572.20. Following the transaction, the director owned 92,173 shares within the firm, valued at $271,910.35. This commerce represents a 39.24% lower of their possession of the inventory. The transaction was disclosed in a authorized submitting with the Securities & Change Fee, which could be accessed by means of this hyperlink.
Alzamend Neuro Inventory Efficiency
Shares of NASDAQ ALZN opened at $2.96 on Friday. The inventory’s 50 day shifting common value is $3.29 and its two-hundred day shifting common value is $6.41. Alzamend Neuro, Inc. has a 52-week low of $2.75 and a 52-week excessive of $135.54.
Analysts Set New Value Targets
Individually, Wall Street Zen upgraded shares of Alzamend Neuro from a “promote” ranking to a “maintain” ranking in a analysis be aware on Saturday, June 14th.
Read Our Latest Report on Alzamend Neuro
Institutional Buyers Weigh In On Alzamend Neuro
A hedge fund not too long ago purchased a brand new stake in Alzamend Neuro inventory. Geode Capital Administration LLC acquired a brand new place in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) within the fourth quarter, in line with the corporate in its most up-to-date disclosure with the Securities and Change Fee (SEC). The fund acquired 33,540 shares of the corporate’s inventory, valued at roughly $39,000. Geode Capital Administration LLC owned 0.62% of Alzamend Neuro on the finish of the newest reporting interval. 49.61% of the inventory is at the moment owned by institutional traders and hedge funds.
About Alzamend Neuro
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical firm, focuses on growing numerous merchandise for the remedy of neurodegenerative and psychiatric problems. The corporate’s pipeline contains AL001, which delivers a therapeutic mixture of lithium, proline, and salicylate for the remedy of Alzheimer’s, bi-polar dysfunction, post-traumatic stress dysfunction, main depressive dysfunction, different neurodegenerative ailments, and psychiatric problems; and ALZN002 stage, which makes use of a technique utilizing a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to revive the flexibility of a affected person’s immunological system to fight Alzheimer’s illness.
See Additionally
This immediate information alert was generated by narrative science expertise and monetary knowledge from InsiderTrades.com with a view to present readers with the quickest and most correct reporting. This story was reviewed by InsiderTrades.com’s editorial staff previous to publication. Please ship any questions or feedback about this story to [email protected].
